Aims: a) To identify which pretreatment clinical or blood parameters were predictive of patient survival in small-cell lung cancer (SCLC) in a retrospective analysis, b) To validate three known prognostic indices: Royal Marsden Model (index 1), London Group (index 2) and Manchester Score (index 3).
Introduction
The introduction of combination chemotherapy has led to improvements in the outcome of patients with smallcell lung cancer (SCLC). Several reports of prognostic factors (PF) have been published since 1981. Variables other than therapy may determine the overall survival duration observed in a series of SCLC patients. Some of these PF are known and can be controlled while others may still be unrecognized [1] [2] [3] [4] [5] [6] [7] [8] . Among patient baseline characteristics, extent of disease, clinical performance status (PS) and weight loss have been identified as consistent PF for survival [2, 3] .
Information on known PF is needed for a proper interpretation of survival data [4] . The current retrospective study was performed in unselected patients referred to a single institution. The aims of this study were: a) to evaluate the impact of pre-treatment characteristics on the prognosis of patients with SCLC; b) to define patient subsets with different survival potentials through the elaboration of a prognostic index (PI); and c) to establish whether a simple system of clinical assessment and blood tests is effective as a prognostic indicator. Thus, we have applied three known prognostic indices: the one established by the Royal Marsden study [5] , that proposed by a London group [6, 7] , and the Manchester score system [8] . The two first indices related prognosis to a simple categorisation based on PS and biochemical parameters. The last score incorporated disease extent in addition to biochemical parameters.
Patients and methods
Data on 341 patients (pts) with SCLC treated between November 1981 and January 1993 in a single institution were retrospectively collected. Histological diagnosis of SCLC was made according to the criteria of the World Health Organization (WHO) [9] and/or the International Association for the Study of Lung Cancer [10] .
Pretreatment characteristics
The stage classifications used were: the one proposed by the Veterans 1 Administration Lung Group (VALG) [11] , with Limited Disease (LD) including supraclavicular nodes and pleural effusion [2, 12] , theTNMsystem [13] and the American Joint Committee grouping (AJQ [3] . Pretreatment diagnostic and staging procedures included physical examination, routine full blood count, blood chemistry, chest radiography, chest tomography, fiberoptic bronchoscopy, isotopic bone scans, isotopic or ultrasonographic liver scans, and computed tomographic (CT) scan of thorax, upper abdomen and central nervous system CT was available from 1984.
The most relevant pretreatment characteristics are summarized in Table 1 . Variables were chosen either because previous studies had indicated a possible effect on prognosis or because such an effect seemed likely. For blood variables, the normal range in our laboratory was taken as the cut-off point. According to the VALCG classification, 211 pts had limited disease (LD) and 130 pts had extended disease (ED)
Treatment plan
Twenty-six patients underwent surgical resection with therapeutic or diagnostic-therapeutic intent. The remaining pts received conventional treatment consisting of chemotherapy with or without radiotherapy for LD and chemotherapy for ED. Response was evaluated using WHO criteria. Since the study spanned 11 years, chemotherapy protocols varied ( Table 2 ). Patients were treated on protocols or received an accepted treatment schedule. In earlier years regimens without platin derivates were applied, whereas in later years, most of the patients received cisplatin-based chemotherapy.
Radiotherapy was administered to 129 pts with LD. The standard treatment consisted of 40-50 Gy on mediastinum and supraclavicular region after complete response (n = 43) or tumor persistence after chemotherapy (n = 86). When prophylactic cranial irradiation was given (n = 14) the dose was 25-30 Gy.
Prognostic models evaluated
The feasibility of the following three models was explored; nevertheless, some of the laboratory parameter values were adapted to the normal range of our hospital.
Firstly -Good prognosis: Karnofsky PS >70, plasma sodium > 136 mmol/l, plasma albumin >39 g/1 and alkaline phosphatase less than 150% above the upper limit for laboratory. -Intermediate prognosis: by exclusion from category 1 and 3. -Bad prognosis: Karnofsky PS <70, plasma sodium <135 mmol/l, plasma albumin <38 g/1, plasma alkaline phosphatase greater than three times the upper normal limit for laboratory. Finally, the Manchester scoring system was designated index 3. This was chosen because it incorporated disease extent and lactate dehydrogenase (LDH) in addition to other biochemial parameters.
Variables with prognostic value were: LDH >450 U/l (upper normal limit), extensive stage, sodium < 132 mmol/l, Karnofsky score <60, alkaline phosphatase >165 U/l (1.5-fold upper normal limit) and bicarbonate <24 mmol/l. One positive point was assigned for each of these.
The score was the total number obtained from the six variables with prognostic value: Good-prognosis group, score 0 and 1; intermediate-prognosis group: score 2 and 3 and poor-prognosis group: score 4+. Abbreviations: AST & ALT -aspartate and alanine transaminases; GGT -gamma-glutamyltranspeptidase; ESR -erithrocyte sedimentation rate; CEA -carcinoembryonic antigen; NSE -neuron-specific enolase; SVCS -superior vein cava syndrome. [17] was used, with a forward stepwise progression procedure employed to determine combinations of tumor or patients' characteristics which were important in predicting survival.
Comparisons were considered to be statistically significant when P-values were less than 0.05.
The BMDP statistical software was applied.
Results

Univariate analysis
Laboratory and clinical variables related to survival (in the group as a whole and in the sets of pts with LD and ED) and the level of prognostic significance are shown in Table 3 .
Multivariate model
Variables selected for multivariate analysis were those with a significant correlation with survival. At the end of the multiple regression analysis only 7 of 22 variables were still significantly related to survival. All of these had been determined in a total of 220 pts ( Table 4 ). The next step was to identify those variables that could modify the model when they were introduced. Variables considered sequentially were: bicarbonate, ALT, ESR, sodium, potassium, alkaline phosphatase, urea, uric acid and age. Thus, only glycemia was eliminated when GGT or bicarbonate were introduced. The remaining variables were not modified after introduction of changes in the ones considered in the analysis. However, inclusion of leukocyte count in the multivariate analysis instead of neutrophil count showed no sig-nificant prognostic value. This result confirmed the prognostic importance of absolute neutrophilia. 
Application of the three prognostic models
Firstly, the application of index 1 was able to distinguish only two prognostic groups (Figure 2 ): good and poor PG. Secondly, we used the criteria of index 2 and it identified three prognostic groups (Figure 3 ).
Finally, index 3 allowed the division of patients into three risk groups (Figure 4 ).
Proposed prognostic index
Once variables with independent prognostic value were recognized, a combination of them was accomplished in order to obtain a Prognostic Index that made it possible to divide patients into risk groups.
Thus, for clinical purposes a simple scoring system was devised: LDH >225 U/l = 1 point, albumin ^3.4 g/dl = 1 point, neutrophils > 7.5 x 10 9 /l = 1 point, extended disease = 1 point, ECOG PS > 1 = 1 point.
CK was not taken into account because it was determined only in 266 cases, which would limit the number of patients considered for distribution into prognostic groups.
The final score was the total number obtained from the five variables selected and was the simplest for clinical use. Previous studies had demonstrated that very little information appears to be lost when this score is used rather than the more complicated Cox analysis [8] .
Prognostic index
-Good-prognosis group: score 0 and 1.
-Intermediate-prognosis group: score 2 and 3.
-Poor-prognosis group: score 4 and 5.
A total of 303 patients were considered for grouping because these five variables had been determined in all of them. Median survival and two-year survival for each PG are shown in Figure 1 .
Commentary
The goal of studies about PF is to explain the heterogeneity observed in the characteristics of patients and in the outcome of diseases in humans. Once PFare known, they can be used to group patients into sets with comparable prognoses: prognostic groups (PG). The identification of PG is made after the elaboration of a PI where many PF are joined and a minimal 'core' of important PF are identified. The predictive ability of a PI must be proven for it to be accepted [4] .
In our univariate analysis age did not reach prognostic value, which accords with some studies [2, 18, 19] and differs from others [3, 20, 21] . Female sex demonstrated a better prognosis in spite of the low number of women. This fact has already been observed [21, 22] . The prognostic significance of pretreatment PS has been recognized before [18, 19, 21, 23] . Likewise, the prognostic value of disease extent according to the VALG recommendation has already been noted [2, 19, [24] [25] [26] . Distribution between LD (61.8%) and ED (38.1%) was close to that mentioned in some studies [27, 28] , although there was a higher proportion of LD patients than of others [29, 30] . However, the wider range in the criteria of LD (with the inclusion of bilateral supraclavicular nodes and ipsilateral isolated pleural effusion) must be considered, and the fact that patients were prospectively unselected. We cannot rule out that staging methodologies could have influenced the ratio LD/ED (CTwas available from 1984).
In patients with LD, the importance of the TNM system has been established in the literature because it renders it possible to divide patients according to mediastinic involvement and to identify those suitable for surgical resection [31, 32] .
Liver and bone involvement had prognostic significance in the global series. The adverse prognosis of liver [23, 30, 33] and bone infiltration [1, 34] have already been pondered. After considering both as the sole site of metastasis in the set of patients with ED, prognosis was similar to that of the remaining patients. This fact has been observed before [30] .
The importance of the number of metastases has been reported [23, 34, 35] . Patients with a single metastatic site demonstrated a better survival. However, this was not verified upon consideration of the different locations separately, which could be due to the low number of patients considered for each metastatic location.
Low albumin was associated with an adverse outcome. Several studies have pointed to its correlation with tumor volume and PS [5, 23, 36, 38] .
Elevated LDH figures conferred a poor prognosis and this coincides with previous reports [8, 19, 23] . Increment of its levels would implicate an increment of tumor mass and would serve as a measurement of the global activity of the disease. Elevated LDH levels could be related to the amount of tumor. In the present series, survival was not different between patients with normal levels of LDH and ED and those with elevated levels of LDH and LD. This might suggest that tumor spread is as critical as the initial amount of tumor, and refutes other previously published results [18] .
The increase of CK conferred a clear adverse prognosis. There are diverse references in the literature about the prognostic importance of CK (especially for the CK-BB isoenzyme) independently of disease extent [39] . Raised CK levels are more frequent in SCLC than in other histologic types of lung cancer, which has suggested a greater energy requirement for SCLC [40] .
Our most original result is probably the prognostic value of glycemia and neuthophil count. The first finding needs to be confirmed since we found no study in the literature about glycemia. On the other hand, neutrophil count has demonstrated prognostic value only in univariate analysis [37] . It is noteworthy that these two latter biologic tests are routinely performed before starting chemotherapy and, consequently, are of importance in common clinical practice.
Some association between neutrophilia and leukocytosis and SCLC has been retrospectively documented [37] and similarly between neutrophilia and NSCLC [41] . This might reflect the production of hematopoietic growth factors by tumor cells, which could be correlated with tumor size or disease extent [41] . Another hypothesis is that an increased leukocyte count could be the marker of infection due to bronchial tumoral obstruction (SCLC tends to have a central location) [27] .
In cancer patients with extended disease and weight loss, extensive changes in energy, carbohydrate, lipid, and protein metabolism have been demonstrated [42, 44] . Glucose intolerance is documented by hyperglycemia and delayed clearance of blood glucose after glucose administration, which may be due to the abnormal presence of insulin or a reduction in insulin receptors in the peripheral tissue. Levels of glycemia could also be related to an elevated production of corticoids (ACTHlike syndrome) [44] .
With respect to the multivariate analysis, the results obtained in other studies have been confirmed. Thus, the independent prognostic value of some variables such as LDH [8, 19, 21] , disease extent [2, 8, 19] , albumin [5, 19, 23] and PS [20, 21, 23] has been demonstrated. However, other variables not described in previous studies such as independent factors (CK and neutrophil count) demonstrated to possess independent prognostic value.
Comparison was not made according to the different chemotherapy schedules. Most patients were treated in a non-protocol manner and were not evaluated to compare results of their treatment with those published in the literature. However, difference according to date of diagnosis was not statistically significant.
In the last fifteen years several models and prognostic indices for defining risk groups have been described. However, they have been applied only occasionally in clinical practice. In this study we have attempted to reproduce the results obtained in three previous reports. These three models were chosen for two reasons: in two of them an index was established without regard for disease extent and the variables used in each model had been determined in most of our patients.
The number of patients included in each of the different models was smaller than the number in the series as a whole. Part of the information is frequently lost by grouping. This phenomenon was seen even in the original studies. The two-year survival probability obtained under the three conditions was similar to that obtained in the studies reported, confirming the predictive ability of the three prognostic models [5] [6] [7] [8] . On the other hand, and especially in the early years, patients with a very poor performance status did not receive treatment, which could have had a minimal influence on ED proportion because the impact of disease extent on performance status has already been established [20] . It probably did not influence our results, however, because we did not observe different survivals according to the date of diagnosis. This fact could only have contributed to the scarcity of the patients in the poor prognostic groups in each of the three indices evaluated. However, the most important purpose must be to distinguish patients who do well from the remainder.
After considering PG established by the new index, the number of patients in each group was quite proportionate. When a new index is created, the objective is to distinguish subsets with prognostic differences in a given population of patients, which constitutes an easier task that the application of an index has already established.
With this study we have lent support to the proposal (established in two of the evaluated models) that laboratory parameters could give information indicating whether or not patients are likely to do well with chemotherapy. Variables other than disease extent or PS (at least albumin or LDH) should be taken into account when designing future clinical trials and should be used for stratification in randomized studies.
